
Bridge program and overseas demand drive another beat-and-raise quarter
Eli Lilly delivered another strong quarter, with revenue rising 39% year-on-year (YoY) to USD 24.4 billion, well above the consensus estimate of USD 22.5 billion. Growth was driven by a 53% increase in sales volume, partially offset by a 15% decline in realised prices. Revenue was also boosted by around USD 900 million of one-off items, such as a USD 410 million Jardiance milestone payment and favourable changes to rebate and discount estimates.
Sales of Mounjaro rose 65% YoY to USD 10.7 billion, ahead of consensus estimates of USD 10.0 billion, while Zepbound sales grew 49% YoY to USD 5.4 billion, above consensus of USD 5.0 billion. Foundayo sales nearly doubled from the previous quarter to USD 184 million, although this fell short of consensus expectations of USD 230 million. Lilly’s broader portfolio also delivered strong growth, with revenue from key products across its Immunology, Oncology and Neuroscience segments doubling YoY.
Non-GAAP gross margin expanded by 0.8 percentage points to 84.4%, driven by a favourable product mix and lower production costs. Non-GAAP EPS rose 7% YoY to USD 7.48, beating the consensus estimate of USD 5.59 by 34%, even after absorbing USD 4.57 per share of acquired in-process research and development (IPR&D) charges, mainly related to the acquisitions of AtaiBeckley and Curevo.
Management raised its full-year 2026 revenue guidance from USD 85.0–87.0 billion to USD 91.0–92.0 billion, attributing the increase to strong underlying performance across its portfolio, including rapid uptake of the Medicare GLP-1 Bridge program in the US and strong Mounjaro sales internationally. Non-GAAP EPS guidance was trimmed from USD 35.50–36.50 to USD 35.00–36.00, as a USD 4.07 increase in underlying EPS at the midpoint was more than offset by the third-quarter IPR&D charges.
Table 1: Eli Lilly’s 3Q26 financial highlights
|
3Q25 |
3Q26 |
Beat/Miss vs Estimate |
YoY change |
|
|
Revenue |
17,601 |
24,397 |
8.3% |
38.6% |
|
Gross Margin |
83.6% |
84.4% |
1.0% |
+0.8pts |
|
Operating Income |
7,849 |
9,039 |
30.4% |
15.2% |
|
Net Income |
6,312 |
6,679 |
33.8% |
5.8% |
|
Diluted EPS |
7.02 |
7.48 |
33.8% |
6.6% |
|
Source: Eli Lilly 3Q Earnings Presentation, Bloomberg. Data as of 30 September 2026. Figures are in USD millions except percentages and per share amounts and reflect non-GAAP numbers. |
||||
Table 2: Strong growth of key products
|
Key Product Revenues |
3Q25 |
3Q26 |
Year-over-Year Change |
|
Mounjaro |
6,515 |
10,723 |
65% |
|
Zepbound |
3,588 |
5,352 |
49% |
|
Jaypirca |
143 |
228 |
59% |
|
Ebglyss |
127 |
202 |
59% |
|
Kisunla |
70 |
193 |
175% |
|
Omvoh |
65 |
114 |
76% |
|
Inluriyo |
- |
73 |
NM |
|
Foundayo |
- |
184 |
NM |
|
Total Revenue (All Products) |
17,601 |
24,397 |
39% |
|
Source: Eli Lilly 3Q Press Release. Data as of 30 September 2026. Figures are in USD millions except percentages. |
|||
Lilly extends its incretin lead as Foundayo gains ground
Lilly continued to gain share in the incretin market. Its share of US incretin analogue prescriptions rose to 63.0% by the end of 3Q26, from 60.9% in 2Q26, while its share of international markets climbed nearly 4 percentage points to 58.4% (Figure 1).
Foundayo is also gaining ground. Around 40% of new US patients starting an oral obesity medicine chose Foundayo by the end of the quarter, up from roughly one in four in late July, and the number of new Foundayo patients doubled from the previous quarter. Even so, it still trails Novo Nordisk’s Wegovy pill, which generated 3Q26 sales of DKK 5.39 billion (about USD 810 million), more than four times Foundayo’s sales.
Further catalysts lie ahead. A US regulatory decision on Foundayo for type 2 diabetes is expected in 4Q26, a sizeable opportunity given that roughly half of US GLP-1 volume is in diabetes. Internationally, Foundayo has launched in the UAE, the UK, Saudi Arabia and Mexico, and has received a positive opinion from the European Medicines Agency’s scientific committee, with EU approval expected by year-end. Lilly plans to launch the drug in more than 40 markets in 2027.
Next-generation therapies are also progressing. In a head-to-head Phase 3 trial in people with type 2 diabetes, retatrutide lowered blood sugar (A1C) by 2.2%, versus 1.8% for the highest dose of Novo’s Ozempic, and delivered weight loss of 20–21%, more than double Ozempic’s 9.4%. Lilly plans to submit retatrutide for US approval in the first quarter of 2027, and is testing it head-to-head against tirzepatide, the active ingredient in Mounjaro and Zepbound, in the ongoing TRIUMPH-5 trial.
Meanwhile, the Medicare GLP-1 Bridge program has exceeded management’s expectations. Since its 1 July launch, more than 500,000 people have filled a prescription for a Lilly medicine through the program, and Lilly’s monthly Bridge prescriptions more than doubled from about 222,000 in July to 527,000 in September (Figure 2). Seven in ten new Bridge patients chose a Lilly obesity medicine (Zepbound or Foundayo), and about 80% of Lilly’s Bridge patients are new to incretin therapy, suggesting the program is expanding the market.
Management is optimistic that Medicare coverage of obesity drugs will continue after the temporary program ends in December 2027. It pointed to strong uptake, appropriate use of the medicines and evidence of cost savings, including a University of Southern California study estimating more than USD 20 billion of Medicare savings over 10 years. CEO David Ricks expects this could lead to permanent coverage through legislative or regulatory change, with obesity drugs likely moving into the standard Medicare Part D drug benefit from 2028.
Employers pulling back on obesity drug coverage, largely due to cost, also remain a concern. A WTW survey of nearly 500 US employers found the share covering GLP-1s for weight loss fell from 57% to 53% in 2026, with 30% of those still covering the drugs considering dropping them. Management, however, expects commercial access to stay relatively stable through 2027, citing positive discussions with employers through its Employer Connect programme and other channels. Patients who lose coverage can also buy Lilly’s medicines directly through LillyDirect, and some companies are moving to a direct-to-employer model, where they drop coverage through their traditional pharmacy program but reimburse part of employees’ out-of-pocket costs. Management expects access gains in 2027 to come mainly from Medicare and Medicaid, which, together with self-pay, carry lower net prices per prescription. While this will weigh on average prices, we expect volume gains to more than offset it.
Figure 1: Lilly continues
to gain share of the incretin market
Figure 2: Uptake of the
Medicare GLP-1 Bridge program is accelerating
New growth engines beyond incretins, funded by strong obesity cash flows
Beyond incretins, revenue from Lilly’s key immunology, oncology and neuroscience products doubled YoY.
In immunology, Ebglyss sales rose 59% YoY to USD 202 million, making it the fastest-growing atopic dermatitis medicine in the US. In oncology, Jaypirca sales grew 59% and the drug won FDA approval for certain previously untreated leukaemia patients, while Inluriyo exited the quarter with a more than 60% share of new US prescriptions in its breast cancer segment. In neuroscience, Kisunla sales jumped 175% YoY, supported by a doubling in Alzheimer’s blood diagnostic tests.
The pipeline points to further diversification. Management highlighted that three-quarters of Lilly’s clinical pipeline is focused on diseases outside obesity (Figure 3). Lilly also continues to pursue acquisitions, with recent deals including AtaiBeckley (psychiatry) and Merida Biosciences (immunology).
Importantly, Lilly can invest for the long term from a position of strength. It faces no major patent expiries on its key products until the next decade, and its incretin business generates substantial cash. As business development head Jacob Van Naarden put it, Lilly does “not need revenue tomorrow”, allowing it to take calculated risks on assets that could drive growth for decades.
Figure 3: Three-fourths of Lilly’s clinical pipeline targets diseases outside obesity

Source: Eli Lilly 3Q Earnings Presentation. Data as of 27 October 2026.
Stronger earnings outlook already reflected in the share price
We have trimmed our 2026 EPS estimate slightly, from USD 36.1 to USD 35.8, as the USD 4.57 per share of IPR&D charges booked in 3Q26 more than offset stronger underlying earnings.
In contrast, we have raised our 2027 and 2028 EPS estimates, reflecting stronger-than-expected incretin demand and market share gains in both the US and international markets. We also expect more durable international growth, as overseas cash-pay demand has extended beyond high-income patients to middle-income households.
Accordingly, we have raised our target price from USD 1,390 to USD 1,567, based on an unchanged fair PE of 26x our 2028 earnings estimate. However, following the share price rally since our last report, this leaves an upside potential of just 8.6% from the 13 November close of USD 1,443.50. We are therefore downgrading Eli Lilly from “Buy” to “Hold”.
Our base case assumes Medicare continues to cover obesity drugs after the temporary Bridge program ends in December 2027, so a lapse in this coverage is a risk to our estimates, as are further cuts to employer coverage.
Overall, we still like Lilly’s market-leading incretin portfolio and growing diversification, but would wait for a more attractive entry point.
Table 3: Projections for Eli Lilly earnings
|
Eli Lilly |
2025 |
2026E |
2027E |
2028E |
|
Earnings Per Share (EPS) |
26.2 |
35.8 |
50.7 |
60.3 |
|
Earnings Growth YoY |
72.4% |
36.8% |
41.4% |
19.0% |
|
PE Ratio (X) |
41.1 |
40.3 |
28.5 |
23.9 |
|
Target Price (based on a fair PE of 26X) |
1,567 |
|||
|
Upside Potential |
8.6% |
|||
|
Source: Bloomberg Finance L.P., iFAST Estimates. Data as of 13 November 2026 |
||||
Figure 4: Share prices are
driven by earnings growth in the long run
Declaration:
This research report was prepared with the assistance of artificial intelligence (AI) tools. iFAST Financial Pte Ltd does not rely exclusively on AI for content generation; the content of this report – including all investment theses, ratings, price targets and conclusions – has been independently reviewed and verified by the research analyst(s) to ensure accuracy and professional integrity.
For specific disclosure, at the time of publication of this report, IFPL (via its connected and associated entities) holds a NIL position in the abovementioned securities. The analyst who produced this report holds a position in Eli Lilly.

